Abstract:Abstract While a number of low-frequency genetic variants of large effect size have been shown to underlie both cardiovascular disease and dementia, recent studies have highlighted the importance of common genetic variants of small effect size, which, in aggregate, are embodied by a polygenic risk score. We investigate the effect of polygenic risk for coronary artery disease on brain atrophy in Alzheimer’s disease using whole-brain volume and put our findings in context with the polygenic risk for Alzheimer’s disease and presumed small vessel disease as quantified by white-matter hyperintensities. We use 730 subjects from the Alzheimer’s disease neuroimaging initiative database to investigate polygenic risk score effects (beyond APOE) on whole-brain volumes, total and regional white-matter hyperintensities and amyloid beta across diagnostic groups. In a subset of these subjects (N = 602), we utilized longitudinal changes in whole-brain volume over 24 months using the boundary shift integral approach. Linear regression and linear mixed-effects models were used to investigate the effect of white-matter hyperintensities at baseline as well as Alzheimer’s disease-polygenic risk score and coronary artery disease-polygenic risk score on whole-brain atrophy and whole-brain atrophy acceleration, respectively. All genetic associations were examined under the oligogenic (P = 1e-5) and the more variant-inclusive polygenic (P = 0.5) scenarios. Results suggest no evidence for a link between the polygenic risk score and markers of Alzheimer’s disease pathology at baseline (when stratified by diagnostic group). However, both Alzheimer’s disease-polygenic risk score and coronary artery disease-polygenic risk score were associated with longitudinal decline in whole-brain volume (Alzheimer’s disease-polygenic risk score t = 3.3, PFDR = 0.007 over 24 months in healthy controls) and surprisingly, under certain conditions, whole-brain volume atrophy is statistically more correlated with cardiac polygenic risk score than Alzheimer’s disease-polygenic risk score (coronary artery disease-polygenic risk score t = 2.1, PFDR = 0.04 over 24 months in the mild cognitive impairment group). Further, in our regional analysis of white-matter hyperintensities, Alzheimer’s disease-polygenic risk score beyond APOE is predictive of white-matter volume in the occipital lobe in Alzheimer’s disease subjects in the polygenic regime. Finally, the rate of change of brain volume (or atrophy acceleration) may be sensitive to Alzheimer’s disease-polygenic risk beyond APOE in healthy individuals (t = 2, P = 0.04). For subjects with mild cognitive impairment, beyond APOE, a more inclusive polygenic risk score including more variants, shows coronary artery disease-polygenic risk score to be more predictive of whole-brain volume atrophy, than an oligogenic approach including fewer larger effect size variants.

Association of whole-person eigen-polygenic risk scores with Alzheimer's disease

Polygenic Risk Score Reveals Genetic Heterogeneity of Alzheimer’s Disease between the Chinese and European Populations

Epistatic Features and Machine Learning Improve Alzheimer's Disease Risk Prediction Over Polygenic Risk Scores

Prediction of clinical diagnosis of Alzheimer’s disease, vascular, mixed, and all-cause dementia by a polygenic risk score and APOE status in a community-based cohort prospectively followed over 17 years

Risk prediction of late-onset Alzheimer’s disease implies an oligogenic architecture

Polygenic Risk Score Effectively Predicts Depression Onset in Alzheimer's Disease Based on Major Depressive Disorder Risk Variants.

Polygenic Hazard Score Associated Multimodal Brain Networks along the Alzheimer's Disease Continuum.

Effects of polygenic risk for Alzheimer’s disease on rate of cognitive decline in normal aging

Improving the Utility of Polygenic Risk Scores as a Biomarker for Alzheimer's Disease

Polygenic Analysis of Late-Onset Alzheimer'S Disease from Mainland China

Neurocognitive trajectory and proteomic signature of inherited risk for Alzheimer's disease

Identifying Genes Associated with Alzheimer's Disease Using Gene-Based Polygenic Risk Score

Polygenic risk score penetrance & recurrence risk in familial Alzheimer disease

Alzheimer's Disease Polygenic Risk Score Is Not Associated With Cognitive Decline Among Older Adults With Type 2 Diabetes

Association of Polygenic Risk Score with Age at Onset and Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease in a Chinese Cohort

Polygenic Risk Scores in Alzheimer’s Disease Genetics: Methodology, Applications, Inclusion, and Diversity

Alzheimer's disease heterogeneity explained by polygenic risk scores derived from brain transcriptomic profiles

A polygenic risk score for Alzheimer’s disease determines the risk of incident dementia in APOE ɛ4 negative individuals over the age of 95: A population‐based cohort study

Association of polygenic risk scores with Alzheimer's disease and plasma biomarkers among Chinese older adults: A community‐based study

Changes in expression of VGF, SPECC1L, HLA-DRA and RANBP3L act with APOE E4 to alter risk for late onset Alzheimer's disease

Polygenic coronary artery disease association with brain atrophy in the cognitively impaired